Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 340

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia

Carette, Simon, Bell, Mary J., Reynolds, W. John, Haraoui, Boulos, Mccain, Glenn A., Bykerk, Vivian P., Edworthy, Steven M., Baron, Murray, Koehler, Barry E., Fam, Adel G., Bellamy, Nicholas, Guimont, Chantal·1994·Arthritis & Rheumatism

Abstract

Objective. To compare the relative efficacy and tolerability of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia, and to identify predictors of response to amitriptyline and cyclobenzaprine. Methods, Two hundred eight patients who fulfilled the American College of Rheumatology criteria for the classification of fibromyalgia were entered into a 6‐month prospective, double‐blind, multicenter trial and were randomized to 1 of 3 treatment groups: amitriptyline, cyclobenzaprine, or placebo. Results. After 1 month, 21%, 12%, and 0% of the amitriptyline, cyclobenzaprine, and placebo patients, respectively, had significant clinical improvement (amitriptyline versus placebo P = 0.002, cyclobenzaprine versus placebo P = 0.02, amitriptyline versus cyclobenzaprine P not significant). These percentages increased to 36%, 33%, and 19%, respectively, at the 6‐month assessment (P not significant). The nature and frequency of side effects reported by patients treated with amitriptyline and those reported by patients treated with cyclobenzaprine were similar. A normal Minnesota Multiphasic Personality Inventory (MMPI) profile at baseline was predictive of clinical improvement at the 1‐month evaluation (odds ratio 3.3, 95% confidence interval 1.2—9.0). However, neither the MMPI profile nor any of the demographic, clinical, or functional parameters evaluated at baseline predicted long‐term response. Conclusion. Our data confirm the short‐term efficacy of amitriptyline and cyclobenzaprine in a small percentage of patients with fibromyalgia. Long‐term efficacy could not be demonstrated because of a higher‐than‐expected placebo response. Predictors of response to these drugs could not be determined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.1780370106

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 340

Metadata

Authors
Carette, S., Bell, M. J., Reynolds, W. J., Haraoui, B., Mccain, G. A., Bykerk, V. P., Edworthy, S. M., Baron, M., Koehler, B. E., Fam, A. G., Bellamy, N., & Guimont, C.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
1994-01
Volume
37
Issue
1
Pages
32-40
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2013721829
Cited by
340
References
35
FWCI
11.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia. https://app.cochat.ai/papers/10.1002/art.1780370106
The paper
Carette, S., Bell, M. J., Reynolds, W. J., Haraoui, B., Mccain, G. A., Bykerk, V. P., Edworthy, S. M., Baron, M., Koehler, B. E., Fam, A. G., Bellamy, N., & Guimont, C. (1994). Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia. Arthritis & Rheumatism. https://doi.org/10.1002/art.1780370106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.